KNSA
What one share of Kiniksa Pharmaceuticals International holds
Pharmaceutical Preparations
We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
Kiniksa Pharmaceuticals International’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $9.36 |
|---|---|
| Profit | $0.91 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $2.04 |
| Cash and investments | $2.48 |
| Book value | $7.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$35.85 | $0.04 | −$27.79 | — | −$49.57 |
| 2018 | — | −$3.49 | $0.18 | −$2.92 | — | $9.45 |
| 2019 | — | −$2.99 | $0.06 | −$2.99 | — | $4.17 |
| 2020 | — | −$2.61 | $0.00 | −$2.21 | — | $5.04 |
| 2021 | $0.56 | −$2.30 | $0.01 | −$1.85 | — | $2.70 |
| 2022 | $3.13 | $2.60 | $0.00 | $0.08 | — | $5.71 |
| 2023 | $3.76 | $0.20 | $0.00 | $0.18 | — | $6.26 |
| 2024 | $5.93 | −$0.60 | $0.00 | $0.36 | — | $6.14 |
| 2025 | $8.58 | $0.75 | $0.02 | $1.73 | — | $7.65 |